Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
Proportion of patients with JIA receiving TNFi, MTX, NSAID, and GC by calendar year. JIA: juvenile idiopathic arthritis; TNFi: tumor necrosis factor inhibitors; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; GC: glucocorticoids.

Table 1.

Patient characteristics for all children with ≥ 1 JIA code and for new TNFi users. Data presented are n (%) unless noted.

JIA: juvenile idiopathic arthritis; TNFi: tumor necrosis factor inhibitors; IQR: interquartile range.

Table 2.

The use of NSAID in the 6 months prior to and the 6 months following new initiation of TNFi use.

	No. NSAID Users No. Prior to New TNFi Use	NSAID Users Following New TNFi Use	p	Mean No. NSAID Prescriptions Prior to New TNFi Use (SD)	Mean No. NSAID Prescriptions Following New TNFi Use (SD)	Mean Change in No. NSAID Prescriptions (95% CI)	p
All new TNFi users, n = 344	194 (56%)	149 (43%)	0.0006	1.6 (1.9)	1.2 (1.8)	−0.4 (0.2–0.6)	0.0003
Prevalent NSAID users, n = 194	194 (100%)	125 (64%)	< 0.0001	2.8 (1.7)	2.0 (2.0)	−0.9 (0.5–1.2)	< 0.0001

NSAID: nonsteroidal antiinflammatory drugs; TNFi: tumor necrosis factor inhibitors.

Table 3.

The use of GC in the 6 months prior to and the 6 months following new initiation of TNFi use.

	No. GC Users Prior to New TNFi Use	No. GC Users Following New TNFi Use	p	Mean Daily GC Dose Prior to New TNFi Use (SD)	Mean Daily GC Dose Following New TNFi Use (SD)	Mean Change in Daily GC Dose (95% CI)	p
All new TNFi users, n = 344	126 (37%)	68 (20%)	< 0.0001	2.7 mg (5.8)	1.6 mg (4.8)	−1.1 mg (0.5–1.6)	0.0002
Prevalent GC users, n = 126	126 (100%)	51 (40%)	< 0.0001	7.3 mg (7.7)	3.9 mg (7.3)	−3.4 mg (2.0–4.9)	< 0.0001

GC: glucocorticoids (in prednisone equivalents); TNFi: tumor necrosis factor inhibitors.